323 related articles for article (PubMed ID: 28499187)
1. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.
Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Jaeschke RR; Sendek K; Styczeń K; Datka W; Koperny M
Pharmacol Rep; 2017 Aug; 69(4):595-601. PubMed ID: 28499187
[TBL] [Abstract][Full Text] [Related]
2. Vortioxetine: a New Treatment for Major Depressive Disorder.
Connolly KR; Thase ME
Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
Sanchez C; Asin KE; Artigas F
Pharmacol Ther; 2015 Jan; 145():43-57. PubMed ID: 25016186
[TBL] [Abstract][Full Text] [Related]
4. Vortioxetine for the treatment of major depressive disorder.
Tritschler L; Felice D; Colle R; Guilloux JP; Corruble E; Gardier AM; David DJ
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
[TBL] [Abstract][Full Text] [Related]
5. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
[TBL] [Abstract][Full Text] [Related]
6. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.
Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Vellante F; Fornaro M; Fiengo A; Mazza M; Vecchiotti R; Perna G; de Bartolomeis A; Martinotti G; Di Giannantonio M; De Berardis D
Expert Rev Neurother; 2016 May; 16(5):483-95. PubMed ID: 27050932
[TBL] [Abstract][Full Text] [Related]
7. Vortioxetine for the treatment of major depression.
Dhir A
Drugs Today (Barc); 2013 Dec; 49(12):781-90. PubMed ID: 24524096
[TBL] [Abstract][Full Text] [Related]
8. Vortioxetine for the treatment of depression.
Pearce EF; Murphy JA
Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
[TBL] [Abstract][Full Text] [Related]
9. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological properties of vortioxetine and its pre-clinical consequences].
David DJ; Tritschler L; Guilloux JP; Gardier AM; Sanchez C; Gaillard R
Encephale; 2016 Feb; 42(1 Suppl 1):1S12-23. PubMed ID: 26879252
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of vortioxetine for the treatment of major depressive disorder.
Dhir A; Sarvaiya J
Expert Rev Neurother; 2014 Dec; 14(12):1349-63. PubMed ID: 25418918
[TBL] [Abstract][Full Text] [Related]
12. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study.
Pehrson AL; Cremers T; Bétry C; van der Hart MG; Jørgensen L; Madsen M; Haddjeri N; Ebert B; Sanchez C
Eur Neuropsychopharmacol; 2013 Feb; 23(2):133-45. PubMed ID: 22612991
[TBL] [Abstract][Full Text] [Related]
13. [Vortioxetine in the treatment of major depression].
de Bartolomeis A; Fagiolini A; Maina G
Riv Psichiatr; 2016; 51(6):215-230. PubMed ID: 27996982
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
15. VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES.
Dziwota E; Olajossy M
Acta Pol Pharm; 2016 Nov; 73(6):1433-1437. PubMed ID: 29634095
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.
Guilloux JP; Mendez-David I; Pehrson A; Guiard BP; Repérant C; Orvoën S; Gardier AM; Hen R; Ebert B; Miller S; Sanchez C; David DJ
Neuropharmacology; 2013 Oct; 73():147-59. PubMed ID: 23721744
[TBL] [Abstract][Full Text] [Related]
17. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review.
De Diego-Adeliño J; Crespo JM; Mora F; Neyra A; Iborra P; Gutiérrez-Rojas L; Salonia SF
Expert Opin Drug Saf; 2022 May; 21(5):673-690. PubMed ID: 34964415
[TBL] [Abstract][Full Text] [Related]
18. Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse.
Nackenoff AG; Simmler LD; Baganz NL; Pehrson AL; Sánchez C; Blakely RD
ACS Chem Neurosci; 2017 May; 8(5):1092-1100. PubMed ID: 28272863
[TBL] [Abstract][Full Text] [Related]
19. [Vortioxetine: a new antidepressant to treat depressive episodes].
Colle R; Corruble E
Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]